Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RASolute 309: zoldonrasib + daraxonrasib versus gemcitabine + nab-paclitaxel in first-line metastatic KRAS G12D-mutated pancreatic adenocarcinoma
2025-524969-24-00Phase 3Authorised
- Sponsor
- Revolution Medicines
- Start
- Oct 2026
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of zoldonrasib and daraxonrasib in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Revolution Medicines. Primary endpoints: Progression-free survival and Overall survival. Planned start Oct 2026; status: authorised.
02
Drugs
zoldonrasibdaraxonrasib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2025-524969-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524969-24-00.